Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis

Research output: Contribution to journalArticle

Standard

Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis. / Andersson, Maria L. E.; Svensson, Bjorn; Petersson, Ingemar; Hafstrom, Ingiald; Albertsson, Kristina; Forslind, Kristina; Heinegård, Dick; Saxne, Tore.

In: BMC Musculoskeletal Disorders, Vol. 14, 229, 2013.

Research output: Contribution to journalArticle

Harvard

APA

CBE

MLA

Vancouver

Author

Andersson, Maria L. E. ; Svensson, Bjorn ; Petersson, Ingemar ; Hafstrom, Ingiald ; Albertsson, Kristina ; Forslind, Kristina ; Heinegård, Dick ; Saxne, Tore. / Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis. In: BMC Musculoskeletal Disorders. 2013 ; Vol. 14.

RIS

TY - JOUR

T1 - Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis

AU - Andersson, Maria L. E.

AU - Svensson, Bjorn

AU - Petersson, Ingemar

AU - Hafstrom, Ingiald

AU - Albertsson, Kristina

AU - Forslind, Kristina

AU - Heinegård, Dick

AU - Saxne, Tore

PY - 2013

Y1 - 2013

N2 - Background: Currently available biomarkers for the early tissue process leading to joint damage in rheumatoid arthritis are insufficient and lack prognostic accuracy, possibly a result of variable activity of the disease over time. This study represents a novel approach to detect an altered activity of the disease process detected as increasing serum-COMP levels over a short time and whether this would correlate with joint damage progression over the first 5 years of disease. Methods: In all, 349 patients from the Swedish BARFOT early RA study were examined. Serum-COMP was analysed by ELISA at diagnosis and after 3 months. Based on changes in serum-COMP levels, three subgroups of patients were defined: those with unchanged levels (change <= 20%) (N=142), decreasing levels (> 20%) (N=173) and increasing levels (> 20%) (N=34). Radiographs of hands and feet were obtained at inclusion, after 1, 2 and 5 years and scored according to Sharp van der Heijde (SHS). Radiographic progression was defined as increase in SHS by >= 5.8. Results: The group of patients with increasing COMP levels showed higher median change in total SHS and erosion scores at 1, 2 and 5 year follow-up compared with the groups with stable or decreasing COMP levels. Furthermore, the odds ratio of radiographic progression was 2.8 (95% CI 1.26-6.38) for patients with increasing COMP levels vs. patients with unchanged levels. The group of patients with increasing COMP levels had higher ESR at inclusion but there were no baseline differences between the groups for age, gender, disease duration, disease activity (DAS28), function (HAQ), CRP, nor presence of rheumatoid factor or anti-CCP. Importantly, neither did changes over the 3-month period in DAS28, HAQ, ESR nor CRP differ between the groups and these variables did not correlate to joint damage progression. Conclusion: Increasing serum-COMP levels between diagnosis and the subsequent 3 months in patients with early RA represents a novel indicator of an activated destructive process in the joint and is a promising tool to identify patients with significant joint damage progression during a 5-year period.

AB - Background: Currently available biomarkers for the early tissue process leading to joint damage in rheumatoid arthritis are insufficient and lack prognostic accuracy, possibly a result of variable activity of the disease over time. This study represents a novel approach to detect an altered activity of the disease process detected as increasing serum-COMP levels over a short time and whether this would correlate with joint damage progression over the first 5 years of disease. Methods: In all, 349 patients from the Swedish BARFOT early RA study were examined. Serum-COMP was analysed by ELISA at diagnosis and after 3 months. Based on changes in serum-COMP levels, three subgroups of patients were defined: those with unchanged levels (change <= 20%) (N=142), decreasing levels (> 20%) (N=173) and increasing levels (> 20%) (N=34). Radiographs of hands and feet were obtained at inclusion, after 1, 2 and 5 years and scored according to Sharp van der Heijde (SHS). Radiographic progression was defined as increase in SHS by >= 5.8. Results: The group of patients with increasing COMP levels showed higher median change in total SHS and erosion scores at 1, 2 and 5 year follow-up compared with the groups with stable or decreasing COMP levels. Furthermore, the odds ratio of radiographic progression was 2.8 (95% CI 1.26-6.38) for patients with increasing COMP levels vs. patients with unchanged levels. The group of patients with increasing COMP levels had higher ESR at inclusion but there were no baseline differences between the groups for age, gender, disease duration, disease activity (DAS28), function (HAQ), CRP, nor presence of rheumatoid factor or anti-CCP. Importantly, neither did changes over the 3-month period in DAS28, HAQ, ESR nor CRP differ between the groups and these variables did not correlate to joint damage progression. Conclusion: Increasing serum-COMP levels between diagnosis and the subsequent 3 months in patients with early RA represents a novel indicator of an activated destructive process in the joint and is a promising tool to identify patients with significant joint damage progression during a 5-year period.

KW - Cartilage oligomeric matrix protein

KW - COMP

KW - Rheumatoid arthritis

KW - Biomarkers

KW - Radiographic joint damage progression

U2 - 10.1186/1471-2474-14-229

DO - 10.1186/1471-2474-14-229

M3 - Article

VL - 14

JO - BMC Musculoskeletal Disorders

JF - BMC Musculoskeletal Disorders

SN - 1471-2474

M1 - 229

ER -